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To test the genetic contribution of rare missense variants in COL4A1 and COL4A2 in which
common variants are genetically associated with sporadic intracerebral hemorrhage (ICH), we
performed rare variant analysis in multiple sequencing data for the risk for sporadic ICH.
Methods
We performed sequencing across 559 Kbp at 13q34 including COL4A1 and COL4A2 among
2,133 individuals (1,055 ICH cases; 1,078 controls) in United States–based and 1,381 individuals
(192 ICH cases; 1,189 controls) from Scotland-based cohorts, followed by sequence annotation,
functional impact prediction, genetic association testing, and in silico thermodynamic modeling.
Results
We identified 107 rare nonsynonymous variants in sporadic ICH, of which 2 missense variants,
rs138269346 (COL4A1I110T) and rs201716258 (COL4A2H203L), were predicted to be highly
functional and occurred inmultiple ICH cases but not in controls from the United States–based
cohort. The minor allele of rs201716258 was also present in Scottish patients with ICH, and
rs138269346 was observed in 2 ICH-free controls with a history of hypertension and myo-
cardial infarction. Rs138269346 was nominally associated with nonlobar ICH risk (p = 0.05),
but not with lobar ICH (p = 0.08), while associations between rs201716258 and ICH subtypes
were nonsignificant (p > 0.12). Both variants were considered pathogenic based on minor allele
frequency (<0.00035 in European populations), predicted functional impact (deleterious or
probably damaging), and in silico modeling studies (substantially altered physical length and
thermal stability of collagen).
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Conclusions
We identified rare missense variants in COL4A1/A2 in association with sporadic ICH. Our annotation and simulation studies
suggest that these variants are highly functional and may represent targets for translational follow-up.
Intracerebral hemorrhage (ICH) accounts for 10%–15% of
strokes but is the most fatal and least treatable stroke type.1-3
More than half of patients with ICH die within the first year
after the disease, and most survivors have prolonged disabil-
ity.3 The molecular pathways underlying ICH remain poorly
understood, limiting therapeutic development.
Genome-wide association studies (GWAS) have identified ge-
netic loci associated with ICH risk and outcome.4,5 We recently
determined a genome-wide significant association for cerebral
small vessel disease (CSVD) including nonlobar ICH and small
vessel ischemic stroke (SVS) with COL4A1 and COL4A2 (col-
lagen IV α chain 1 and 2) at 13q34,6 validating previous studies.7
Rare mutations that most frequently affect Gly residues in the
Gly-Xaa-Yaa repeat inCOL4A1/A2 cause mendelian early-onset
cerebrovascular disease, ocular dysgenesis, and myopathy.8-12
However, the full spectrum of effects of COL4A1/A2mutations
remain incompletely characterized.7,13,14 Sequencing of a few
families or small number of patients (n < 100) suggested rare
variants in COL4A1/A2 can contribute to sporadic ICH.9-15
To identify rare coding variants in COL4A1/A2 that may un-
derlie the aforementioned GWAS association with ICH and
SVS, we performed targeted sequencing of the 13q34 region in
United States–based studies (1,055 ICH cases and 1,078 ICH-
free controls) as well as exonic sequencing of this locus in 192
ICH cases and whole genome sequencing (WGS) of 1,189
ICH-free controls from Scotland. We present annotation re-
sults, prediction of deleteriousness, and case/control segrega-
tion of rare variants across 13q34 from these datasets.
Methods
Standard Protocol Approvals, Registrations,
and Participant Consents
The study protocols were approved for enrollment of the
United States–based cohorts (Gene Discovery for Warfarin-
Related Intracerebral Hemorrhage [GOCHA] and Ethnic/
Racial Variation in Intracerebral Hemorrhage [ERICH]) and
the Scotland-based cohorts (the Lothian study of In-
tracerebral Haemorrhage Pathology, Imaging and Neurologic
Outcome [LINCHPIN] and Lothian Birth Cohorts [LBC])
by the institutional review boards of Massachusetts General
Hospital and University of Edinburgh. Informed consent was
obtained from participants or an appropriate legal surrogate
according to all recruiting sites.
Study Participants
United States–Based Participants
We collected DNA and phenotyping data on 1,055 patients
with ICH (534 lobar and 521 nonlobar ICH) and 1,078 ICH-
free controls from GOCHA5 and ERICH.16 There is no
overlap between the participants in the present study and
those included in previous targeted sequencing studies of
COL4A1/A2.13,17 A total of 145 participants (18 ICH and 176
controls) in this study appeared in the previous ICH GWAS.5
Scotland-Based Participants
We collected DNA and phenotyping data on 192 ICH cases
(40 lobar and 152 nonlobar) from LINCHPIN among the
sample registered in the Edinburgh Lothian Audit of the
Treatment of Cerebral Hemorrhage study.18
As a control population for the LINCHPIN cohort, we selected
clinical and sequencing data from 1,189 individuals from the
LBC study as an ethnically and geographically matched stroke-
free control population to cases. Self-reported ethnicity of the
patients with ICH and controls was white British.19 The LBC
study recruited people living in Edinburgh and the Lothians
who were born either in 1921 or 1936. Individuals who self-
reported stroke were removed for this study.
Demographic information for the 2,133 United States–based
and 1,381 Scotland-based participants are presented in
table 1.
Glossary
CADD = combined annotation-dependent deletion;CSVD = cerebral small vessel disease; ERICH = Ethnic/Racial Variation in
Intracerebral Hemorrhage;GATK = Genome Analysis Toolkit;GOCHA = Gene Discovery for Warfarin-Related Intracerebral
Hemorrhage; GWAS = genome-wide association studies; ICD-10 = International Classification of Diseases–10; ICH =
intracerebral hemorrhage; LBC = Lothian Birth Cohorts; LD = linkage disequilibrium; LINCHPIN = Lothian study of
Intracerebral Haemorrhage Pathology, Imaging and Neurologic Outcome; MAF = minor allele frequency; MD = molecular
dynamics; ns = nanoseconds; PDB = Protein Data Bank;QC = quality control; SNP = single nucleotide polymorphism; SVS =
small vessel ischemic stroke; UKB = UK Biobank; VEP = variant effect predictor; WES = whole exome sequencing; WGS =
whole genome sequencing.
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Targeted Sequencing at 13q34 and Quality
Control (GOCHA/ERICH and LINCHPIN)
We performed targeted sequencing across 559 Kbp at 13q34
(chr13:110,701,882–111,265,349) including COL4A1/A2
for 2,133 individuals (1,055 ICH cases and 1,078 controls)
in GOCHA/ERICH on the 96plex Nimblegen SeqCap
platform and for 192 ICH cases in LINCHPIN on the
NextSeq 550 platform. The reads with high quality are
aligned to the human genome (GRCh37) using BWA
(version 0.7.10).20 We applied preprocessing steps including
duplicate removal, local realignment, indel realignment us-
ing Genome Analysis Toolkit (GATK) IndelRealigner, and
base quality recalibration using GATK Base Recalibration
before the calling. Then GATK best practices pipeline was
used for calling the variants from those 2 different platforms,
separately. The variants were called and filtered using
HaplotypeCaller.
Variants passing the GATK variant quality score recalibration
metric were retained. We included only single nucleotide
variants or indels with a depth of 10 or higher. We excluded
variants with a call rate <0.98, case–control call rate difference
>0.005, and differential missingness between cases and con-
trols (p < 0.05). Samples were excluded if they had a low
average call rate (<0.98), low mean sequence depth (<30),
low mean genotype quality (<85), or differential missingness
between cases and controls (p < 0.05) and Hardy-Weinberg
equilibrium test (p value < 10−6) on cases and controls
separately.
Whole Genome Sequencing (LBC)
WGS of the LBC sample has been performed previously, with
sequencing protocol and quality control (QC) metrics as
reported.21 The variants selected from the GOCHA/ERICH
and LINCHPIN studies were further evaluated in the LBC
sequencing data as a control population.
Variant Selection and Annotation
We used the Ensembl variant effect predictor (VEP) soft-
ware to annotate functional consequences of variants with
the Ensembl annotation database on human genome as-
semble GRCh37.22 VEP provides various information of
functional consequences of variants (splice acceptor variant,
splice donor variant, start lost, stop lost, stop gained,
frameshift variant, inframe insertion, inframe deletion, and
missense variant) and functional impacts predicted by SIFT
(deleterious or tolerate),23 PolyPhen (probably damaging,
possibly damaging, benign, or unknown),24 combined
annotation-dependent deletion (CADD),25 and LoFtool
(0–1).26 We also used SnpEff, which categorizes the effects
of variants by their genomic locations (e.g., introns, regula-
tory sites, splicing, missenses, nonsense) into high, moder-
ate, low, or modifier.27 We selected nonsynonymous variants
with high/moderate by SnpEff, deleterious by SIFT,
probably/possibly damaging by PolyPhen, CADD scores
>20.0, and LoFtool scores <0.1 in the GOCHA/ERICH and
LINCHPIN datasets.
Single-Variant and Variant-Set Association
Tests in GOCHA/ERICH
We used the CATS online calculator28 to estimate power to
detect ICH association for single variant analysis. We per-
formed single-variant association tests of those variants selected
by annotation methods for the ICH risk by subtype (all-mixed,
lobar, and nonlobar ICH) using logistic regression in R (r-
project.org/). The association models were adjusted for age
and sex. Significance thresholds for the single variant test was
set as α = 0.05 with Bonferroni correction for the numbers of
single variants (number of variants: 39; p < 1.28 × 10−3).
Identification and Selection of Potential Causal
Rare Variants in ICH (GOCHA/ERICH)
Because our sample size remained extremely underpowered
for identifying rare functional variants by conventional asso-
ciation tests, we focused on rare nonsynonymous variants in
COL4A1/A2, particularly those that occur in more than 1
ICH case but not in controls, or in more than 1 control but
not in cases. Variants were first explored in GOCHA/ERICH
as a discovery dataset and then examined in LINCHPIN and
LBC as an external validation of the findings in an in-
dependent population.
We applied PLINK29 software to assess linkage disequilib-
rium (LD) and haplotype inferences at this locus, testing
whether the common single nucleotide polymorphism (SNP),
rs9515201, previously identified in a GWAS of CSVD risk,
lies within a haplotype with our identified rare variants.
Because the genetic architectures of lobar and nonlobar ICH are
known to differ,5 we tested ICH subtype-specific effects for
identified variants using the BinomiRare exact test,30 which uses
Poisson-binomial probabilities to calculate the association
strength of variants based on the probabilities of diseased indi-
viduals carrying minor alleles of the variants under the null hy-
pothesis that the variants are not associated with the disease. A
classical logistic regression analysis was not applied for single-
variant test because our selected variants occur only in 1 group
(e.g., cases or controls), but not both.31 The BinomiRare re-
gression models for ICH subtypes were adjusted for age and sex.
Our identified variants were evaluated using gnomAD32 for
allele frequencies across populations and Geno2MP
(geno2mp.gs.washington.edu/Geno2MP) for phenomic ef-
fect in carriers with variants or their family members.33
To further assess our selected variants, we also explored the
recent whole exome sequencing (WES) of 200,000 individuals
in UK Biobank (UKB).34,35 We leveraged 137,766 unrelated
British White individuals based on kinship relatedness (re-
moving at least 1 of a related pair of individuals) and predicted
ancestries from principal components for population structure
provided by the UKB.36 For ICH-related phenotypes, we used
2 traits in the electric health record including ICD-10 code for
ICH (I61; UKB field number 41,202) and “vascular/heart
problems diagnosed by doctor” (UKB field number 6,150).
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The age at onset for these conditions was not available in the
UKB database. The differences in the numbers of carriers of our
selected variants and noncarriers between cases and controls in
the UKB was examined by a χ2 test.
Analysis of Previously Identified Variants on
COL4A1/A2 in GOCHA/ERICH
We investigated coding variants in COL4A1/A2 previously
identified by other sequencing studies in ICH (rs200786329,13
rs117412802, rs62621875, and rs20110574717) or its related
diseases including hereditary angiopathy, nephropathy,
aneurysms, and cramps (rs113994104, rs113994105, and
rs113994106),12 small vessel disease (rs121912857 and
rs113994107),9 cerebrovascular disease (rs672601346),37
and porencephaly (rs113994112,8 rs11399411415). The
information about their positions and amino acid changes
are provided in table e-1 (data available from Dryad, doi.
org/10.5061/dryad.z34tmpgcq). Previously reported
variants that were also identified in our sequencing data
were analyzed for association with ICH risk using
BinomiRare.
External Validation of Selected Variants in
Scotland-Based Datasets
Selected nonsynonymous rare variants appearing only in cases
or controls in the United States–based dataset were explored
for validation in LINCHPIN and LBC to determine whether
they segregated with cases or controls in these independent
datasets. Because LINCHPIN and LBC utilized different re-
cruitment methods and were sequenced using different ap-
proaches, discovery of candidate variants in these datasets for
validation in the United States–based GOCHA/ERICH cases
was not feasible due to concerns for bias.
In Silico Modeling of Protein Structure and
Thermal Stability of Identified Variants
We further assessed structural effects of selected variants onprotein
structures of COL4A1/A2 using molecular dynamics (MD) sim-
ulation. The α chains in COL4A1 and COL4A2 (figure 1A) in-
teract to form 1 triple-helical collagen type IV protomer,
α1α1α2(IV), that consists of 3 protein domains: N-terminal 7S,
central triple-helical collagen, and C-terminal NC1 (figure 1B).
Thus far, the triple-helical collagen structure for α1α1α2(IV) has
not been experimentally determined in the Protein Data Bank
(PDB; rcsb.org). Therefore, we predicted the tertiary heterotrimer
structure of α1α1α2(IV)molecule using protein secondary/tertiary
structure prediction tools including PSIPRED,38 PFAM,39 and
BLASTp (blast.ncbi.nlm.nih.gov/Blast.cgi).40 Briefly, we used the
α1α1α2(IV) structure (PDB ID: 2CUO)41 as a template and
predicted 2 structure models for our selected variant in COL4A1
according to the number of copies of its mutations such as
COL4A1sWT/mt/COL4A2WT and COL4A1smt/mt/COL4A2WT
and 1model for the variant inCOL4A2 such as COL4A1sWT/WT/
COL4A2mt (figure 2A). To compare structural effects of our
variants on α1α1α2(IV), we also generated additional structure
models for 2 previously reported variants including rs200786329
(COL4A1)13 and rs117412802 (COL4A2).17 These 2 variants
were chosen for the comparison because rs200786329COL4A1 and
rs117412802COL4A2 were most recently identified in targeted se-
quencing of sporadic ICH cases, other than familial early-onset
type IV collagen-related diseases. Moreover, our selected vari-
ants were located in the same Gly-Xaa-Yaa pattern or the
same functional domain. Furthermore, rs200786329COL4A1
and rs117412802COL4A2 showed strong functional changes in
terms of intracellular accumulation and extracellular deficiency
of COL4A1 or COL4A2 protein levels compared to other
variants.13,17
MD simulations were performed with the predicted tertiary
structures of α1α1α2(IV) molecules containing our identified
variants and the 2 previously reported variants using DES-
MOND (deshawresearch.com/resources_desmond.html)42 as
described43 across 500 nanoseconds (ns). We included a mod-
eling assumption that the atompositions of replaced amino acids
stabilized after 100 ns from the start.Maestro (schrodinger.com/
maestro; Schrödinger, LLC, 2016) was used to extract and an-
alyze 800 sequential snapshots of simulated protein structures of
COL4A1 and COL4A2 across 400 ns (100–500 ns).
In addition, the effect of the tripeptide composition (Gly-
Xaa-Yaa) containing our identified variants on collagen tri-
ple helix stability was estimated using the collagen thermal
stability calculator (compbio.cs.princeton.edu/csc),44 which
predicts the melting temperature (Tm).
Table 1 Sample Demographics
GOCHA and ERICH studies LINCHPIN
LBC, controlsLobar ICH Nonlobar ICH Controls Lobar ICH Nonlobar ICH
Total (% female) 534 (50.9) 521 (38.35) 1,078 (44.9) 40 (52.5) 152 (40) 1189 (52)
Age, y, mean (SD) 73.0 (12.6) 69.3 (13.3) 70.2 (12.3) 80.2 (7.6) 70 (14.7) 77.9 (5.9)
ICH volume, mL, mean (SD) 36.0 (33.8) 15.1 (19.8) — — — —
ICH volume, mL, median (IQR) 24.2 (40.9) 8.3 (14.6) — — — —
Abbreviations: ERICH = Ethnic/Racial Variation in Intracerebral Hemorrhage; GOCHA =Gene Discovery forWarfarin-Related Intracerebral Hemorrhage; ICH =
intracerebral hemorrhage; IQR = interquartile range; LBC = Lothian Birth Cohorts; LINCHPIN = Lothian study of Intracerebral Haemorrhage Pathology,
Imaging and Neurologic Outcome.
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Figure 1Highly Functional Nonsynonymous Variants Appearing in PatientsWith Intracerebral Hemorrhage (ICH) Predicted
by Various Annotation Methods and Selected COL4A1 and COL4A2 Variants
(A) Highly functional nonsynonymous
variants appearing in ICH cases pre-
dicted by annotationmethods including
SnpEff (high or moderate), SIFT (dele-
terious), PolyPhen (probably/possibly
damaging), combined annotation-de-
pendent deletion (CADD) (>20.0), and
LoFtool (>0.1). Green: N-terminal 7S
domain; blue: triple helix collagen do-
main; brown: C-terminal NC domain.
*Variants that exist in both datasets. (B)
Selected COL4A1 and COL4A2 variants.
ERICH = Ethnic/Racial Variation in In-
tracerebral Hemorrhage; GOCHA =
Gene Discovery for Warfarin-Related
Intracerebral Hemorrhage.
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Data Availability
Sequencing data used in this study are available on dbGAP
(ncbi.nlm.nih.gov/gap/; accession ID: phs000416.v2.p1).
Additional data supporting these findings are available by the
authors upon reasonable request.
Results
Identification and Genetic Association Tests of
Rare Variants in COL4A1/A2
Following targeted sequencing and stringent QC of the 13q34
region in the United States–based GOCHA/ERICH studies,
we retained 1,055 patients with ICH and 1,078 ICH-free
controls with 11,815 variants. Among these variants, 0.91%
were nonsynonymous (106 missense, 1 nonsense) and 0.70%
were synonymous coding variants.
In the Scotland-based LINCHPIN study, 192 patients with
ICH remained after QC with 1,380 variants at the 13q34 locus.
From these, 1.01% were nonsynonymous (15 missense and 1
nonsense) and 1.88% were synonymous coding variants.
Selecting for nonsynonymous variants with high/moderate im-
pact by SnpEff, deleterious predicted by SIFT, probably/possibly
damaging predicted by PolyPhen, CADD scores >20.0, and
LoFtool scores >0.1, we were left with 39 variants in GOCHA/
ERICH and 4 variants in LINCHPIN, with 3 of these missense
variants, including rs34004222, rs117412802, and rs12877501,
common between studies. These nonsynonymous variants,
predicted to be highly functional based on multiple annotation
methods, are shown in figure 1A. None of these variants is in
significant LD (r2 > 0.4) with rs9515201, the leading common
variant that we previously identified in a recent CSVD GWAS.6
Detailed information on these variants appears in table e-2 (data
available from Dryad, doi.org/10.5061/dryad.z34tmpgcq). An-
notation information for all detected variants in both sequencing
datasets is described in detail in table e-3 (GOCHA/ERICH)
and table e-4 (LINCHPIN) (data available fromDryad, doi.org/
10.5061/dryad.z34tmpgcq).
According to our statistical power calculation (figure e-1, doi.
org/10.5061/dryad.z34tmpgcq), we have extremely limited
power (less than 20%) for detecting genetic association of such
a rare variant (minor allele frequency [MAF] <0.001) with risk
of sporadic ICH. We therefore limited single variant tests to
those 39 variants but did not observe a variant with significant
(p < 1.2 × 10−3) association with ICH subtypes (table e-5, data
available from Dryad, doi.org/10.5061/dryad.z34tmpgcq).
Selection of Potential Causal Variants in
ICH (GOCHA/ERICH)
Due to this expected low statistical power for single rare variant
discovery in the United States–based GOCHA/ERICH data-
set, we chose to focus on nonsynonymous mutations that ap-
pear in at least 2 participants exclusively in 1 group (e.g., ICH)
but is absent in the other group (e.g., ICH-free controls). We
did not observe any nonsynonymous variants that occurred in
at least 2 controls but not in cases, but we did identify 2 rare
missense variants (rs138269346 and rs201716258) appearing
in at least 2 ICH cases without occurrence in the controls
(table 2). rs138269346 (COL4A1 Ile110Thr) is in exon 5 of
COL4A1 corresponding to the N-terminal 7S domain and
rs201716258 (COL4A2 His203Leu) is in exon 10 of COL4A2
corresponding to the triple-helix collagen domain where it af-
fects an X residue of the Gly-Xaa-Yaa repeat (figure 1B).
rs138269346COL4A1 was present in 4 ICH cases (2 lobar and
2 nonlobar ICH cases) and rs201716258COL4A2 was observed
in another 2 ICH cases (1 lobar and 1 nonlobar ICH case).
These ICH cases were each heterozygous for the minor alleles
of these variants and no individual carried the minor alleles of
both variants. These variants were not associated with age at
disease onset, sex, or ICH volume (table e-6, data available
from Dryad, doi.org/10.5061/dryad.z34tmpgcq).
According to our LD calculation and haplotype analysis, these
2 rare variants are not in LD (r2 < 0.01) with the lead SNP of
our previous GWAS, rs9515201,6 and we did not observe
haplotypes carrying minor alleles of the identified rare variants
and rs9515201 (table e-7, data available from Dryad, doi.org/
10.5061/dryad.z34tmpgcq).
Functional Annotations of rs138269346
and rs201716258
Based on gnomAD, these 2 variants are rare in European
populations (MAF <0.0005) and even rarer in other pop-
ulations (table 2). Rs138269346COL4A1 was deemed path-
ogenic due to its annotation across multiple prediction
tools: moderate by SnpEff, deleterious by SIFT, probably
damaging by PolyPhen, and probably damaging by LoF-
tool. It showed a very high CADD score of 23.8, suggesting
that this variant is among the top 0.42% (10−2.38) of most
predicted deleterious variants in the human genome. The
other variant, rs201716258COL4A2, was also considered to
have a negative effect by SnpEff (moderate) and LoFtool
(probably damaging), but not by SIFT (tolerated), Poly-
Phen (benign), and CADD (4.7).
Validation of rs138269346 and rs201716258 in
Scotland-Based Participants
We set out to validate our identified variants using the in-
dependent LINCHPIN dataset. We detected 2 patients with
ICH who carry the minor allele of rs201716258COL4A2 but no
carriers for rs138269346COL4A1. For rs201716258, both indi-
viduals developed nonlobar ICH in the right ventricle (ICH
epicenter was lentiform) with a low small vessel disease score.45
The ages of patients (1 male, 1 female) were 85 and 73 at the
time of ICH, and there was no history of ischemic stroke.
Turning to the population-basedLBCcohort, we identified 2 ICH-
free controls who carry theminor allele of rs138269346COL4A1 but
no carriers for rs201716258COL4A2. One of these 2 ICH-free
controls carrying the rs138269346COL4A1 in LBC self-reported a
history of hypertension and myocardial infarction.
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Further Evaluation of rs138269346 and
rs201716258 in Geno2MP and UKB
Within individuals contributing to theGeno2MP database, carriers
of these variants expressed phenotypic abnormalities previously
identified in patients with rare collagen IV mutation syndromes.14
In Geno2MP, we found 5 heterozygous rs138269346COL4A1 car-
riers and 6 heterozygous rs201716258COL4A2 carriers (table e-8,
data available from Dryad, doi.org/10.5061/dryad.z34tmpgcq).
Figure 2 Protein Structure Prediction and Molecular Dynamics Simulation
(A) Procedure of protein structure prediction. (B) Comparison of physical lengths of protein prediction models affected by our identified variants including
rs138269346 (CO4A1) and rs20176258 (COL4A2) in black as well as the previously reported variants including rs200786329 (COL4A1)17 and rs117412802
(COL4A2)21 in gray. SNP = single nucleotide polymorphism.
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One of the rs138269346COL4A1 carriers had multiple abnor-
malities in the eyes and the cardiovascular and nervous systems,
and relatives of the other 4 carriers also had abnormalities in the
eye,musculature, and cardiovascular and nervous systems. Two
of rs201716258COL4A2 carriers had abnormalities in the ears
and the cardiovascular system, respectively, and the relatives of
the other 4 carriers also had abnormalities in the nervous sys-
tem or musculature.
Among the 137,766 unrelated individuals in the 200K WES
(table e-9), we found 1 rs138269346 carrier but none for
rs201716258 out of 276 proxy patients with ICH (by ICD-10
code I61). Out of 41,032 individuals with vascular/heart
problems, there are 33 carriers for rs138269346 and 63 car-
riers for rs201716258. According to our χ2 analysis,
rs138269346 was nominally associated with the proxy ICH
(χ2 = 3.4; p = 0.063) although there is only 1 proxy ICH case
carrying rs138269346. We did not observe significant asso-
ciation in the rest of the χ2 tests (table e-10, data available
from Dryad, doi.org/10.5061/dryad.z34tmpgcq).
Genetic Association Tests With ICH Subtypes
To determine which ICH subtype is relevant to these variants,
we employed BinomiRare (table 3), which revealed that
rs138269346COL4A1 is nominally associated with risk for
nonlobar ICH (p = 0.054) and less associated with lobar ICH
(p = 0.077) and all-mixed ICH (p = 0.090). However,
rs201716258COL4A2 did not carry a significant association
with any ICH subtype (all p values > 0.12).
Among the previously reported variants in COL4A1/A2, we
could detect 3 nonsynonymous variants in COL4A2, including
rs117412802, rs62621875, and rs201105747, which were pre-
viously reported in only patients with ICH and not in controls.17
However, in the GOCHA/ERICH dataset, we found carriers of
these variants in both ICH cases (carriers of rs117412802: 20;
and rs62621875: 1) and controls (rs117412802: 24; and
rs62621875: 1). We identified rs201105747 only in 1 control.
From the LINCHPIN dataset, we found only rs117412802
among 4 patients with ICH (3 lobar and 1 nonlobar ICH). We
found no significant associations of these observed variants with
ICH risk from BinomiRare (table e-11, data available from
Dryad, doi.org/10.5061/dryad.z34tmpgcq).
In Silico Functional Analysis of rs138269346
and rs201716258
To gain insight into any structural potential consequences of
these 2 missense variants, we performed MD simulations.
Based on α chain composition of α1α1α2(IV), each protomer
can contain 1 or 2 variant α1(IV) molecules and 1 α2(IV). We
therefore constructed 2 structuralmodels for rs138269346COL4A1:
COL4A1sWT/I110T/COL4A2WT and COL4A1sI110T/I110T/
COL4A2WT. Next, for rs201716258COL4A2, 1 structure model
was predicted: COL4A1sWT/WT/COL4A2H203L (figure 2A).
From these simulations, we observed that 2 mutation struc-
tures of rs138269346COL4A1, COL4A1sWT/I110T/COL4A1WT
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of 16.59 ångströms (Å; equal to 10−10m) (SD5.58Å) and 12.64Å
(SD 4.29 Å), respectively (figure 2B). These are 14.9% and 35.1%
shorter than the average length of the wild type (average 19.49 Å;
SD 6.41 Å). Likewise, we also found that themutated structure for
rs201716258COL4A2, COL4A1WT/WT/COL4A2H203L (average
19.13 Å; SD 6.03 Å), became 15.7% shorter than the wild type
(average 22.70 Å; SD 5.94 Å).
For comparison, we also generated structural models of the
previously reported COL4A1/A2 variants rs200786329COL4A1
and rs117412802COL4A2. Interestingly, we found the same
pattern in the simulations of the structure models with muta-
tions of the previously reported variants. The average
lengths of those mutant forms for rs200786329COL4A1 and
rs117412802COL4A2 are 9.7%–25.8% shorter than their wild
types (figure 2B).
It is well established that the amino acid sequence of the
collagenous domain and mutations in collagen influence the
thermal stability and melting temperature of the triple helix.46
According to the collagen stability calculator,44 COL4A1I100T
reduces predicted Tm by 2.2°C compared to COL4A1
wt, while
COL4A2H203L increases the Tm by 2.1–3.1°C compared to
COL4A2wt (figure e-2, data available from Dryad, doi.org/10.
5061/dryad.z34tmpgcq), further lending support to their
functionality.
Discussion
We conducted a targeted sequencing study of 1,055 ICH
cases and 1,078 controls, and an additional dataset (192 ICH
cases) at the 13q34 locus, which we and others have pre-
viously identified in genetic association studies for ICH and
related manifestations of CSVD.6,7 13q34 has been the target
of prior sequencing studies in ICH, but the sample size in this
current study (n = 2,325) is approximately 10 times larger
than those prior efforts (n < 200).8,9,12,13,15,17,37 However,
even with this boost in sample size, statistical power remains
low for rare variants, so we focused on nonsynonymous var-
iants appearing only in ICH cases but not in controls to
restrict our search to the most likely pathogenic variants. Our
study identified 2 novel rare missense variants in COL4A1/
COL4A2, appearing in cases only in our discovery dataset that
(1) are predicted to have damaging effects, (2) are not in LD
with common SNP identified in the previous GWAS for
CSVD, and (3) are predicted to substantially alter the physical
length and the thermal stability of the type IV collagens.
Furthermore, despite the limited statistical power of our
sample size, we did observe a nominally significant association
at rs138269346COL4A1 for nonlobar ICH risk.
In our attempt to externally validate these results in in-
dependent datasets, we detected 2 patients with ICH carrying
rs201716258COL4A2 in LINCHPIN. No ICH case carriers for
rs138269346COL4A1 were found, although 2 individuals with
this variant were identified in the LBC control population.
Given the size difference between the case populations in the
2 studies and the differences in recruitment between the case/
control datasets and LBC, the significance of this replication
failure at rs138269346COL4A1 is unclear.
The majority of mendelian disease–associated mutations in
COL4A1/A2 identified to date affect the Gly residue in the Gly-
Xaa-Yaa repeat pattern, which is necessary for stable triple-helix
formation, and more mutations have been described in CO-
L4A1 than COL4A2.14 However, the amino acids of our se-
lected variants are located on the X residue in the pattern.
Among the previously identified mutations for sporadic ICH,
P352Lrs200786329 (COL4A1)13 and E11223Grs117412802 (CO-
L4A2)17 are also located on non-Gly residue in the tripeptide
pattern, the Y and X residues, respectively. These previous
variants (rs200786329 and rs117412802) significantly reduced
the ratio of extracellular to intracellular COL4A1 or COL4A2
proteins compared to wild types in cultured cells, which is
considered as a potential pathogenic mechanism underlying
the type IV collagens related diseases.13,17 Interestingly, our
MD simulation shows that these previous variants
(rs20078632913 and rs11741280217) as well as our new vari-
ants (rs138269346 and rs20176258) substantially shorten the
physical lengths of triple-helical structures, indicating that al-
tered protein structures such as shortening of the helical do-
mains could lead to changes in the protein functions including
secretion of type IV collagen into extracellular matrix or se-
cretion of mutant protein. In this regard, our thermal stability
study predicted that COLl4A1I100T decreases (−2.2°C) and
COL4A2H203L increases (+2.1–3.1°C) Tm of collagen struc-
tures. These changes are not small in magnitude compared to
the 2°C reduction affected by mendelian disease–associated
Col2a1 mutations.47 Therefore, it also may be possible that our
identified variants exert their effects on type IV collagen
Table 3 Genetic Association Test Summary of the COL4A1/A2 Variants Using BinomiRare
Variant ID (effect
allele)



















rs138269346 (G) 4 2.05 0.09 2 0.79 0.08 2 0.66 0.05
rs201716258 (T) 2 0.98 0.12 1 0.28 0.14 1 0.27 0.13
Abbreviation: ICH = intracerebral hemorrhage.
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function through affecting the thermal stability of collagen,
analogous to other collagen mutations.
Our study has several limitations. First, due to limited statistical
power, we focused on rare variants appearing only in ICH cases
but not controls, which could be considered conservative and
increase false-negative associations for variants with low pene-
trance. Furthermore, we lack an analogous case/control ICH
dataset with deep sequencing for direct validation of our ob-
served variants. Targeted sequencing of 13q34 in LINCHPIN
allowed us to verify the existence of rs201716258 in ICH cases,
but the relatively small sample size and substantial difference in
proportions of ICH subtypes compared to the discovery dataset
makes the lack of observation of rs138269346 inconclusive. The
population-based subjects from LBC are a welcome adjunct to
the LINCHPIN ICH cases, but the varying burden of ICH-
relevant disease histories and comorbidities and prospective
nature of the LBC study, which is not continually updated, make
interpretation of the appearance of rs138269346 in ICH-free
individuals challenging. Due to the lack of genome-wide geno-
typing on the vast majority of subjects, population structure
could not be assessed and adjusted for in our single variant
association tests. While interesting and supportive of known
phenotypic associations in rare COL4A1/A2 syndromes, care
must be taken in interpretation of phenotypes of variant carriers
in Geno2MAP as this database is not a representative population
sample and does not provide data to permit testing of statistical
enrichment of variants. We observed differences in predicted
effects of our identified variants across annotation methods.
However, annotation methods could generate substantially dif-
ferent predictions of variant effects due to variation in the
weighting of variant conservation and other features.48,49 Be-
cause of their rarity, imputation of these variants in existing ICH
GWAS datasets using the HRC and TOPMed reference panels
return very poor imputation quality scores, preventing additional
forms of replication at this time.
Furthermore, there are challenges in integrating UKB data into
our study. First, heterogeneous phenotyping of ICH cases in
the UKB is a major concern that could substantially affect our
genetic models.50 For example, ICH status based on the ICD-
10 code in electric health records is less precise than manual
phenotyping of ICH cases due to a lack of distinction between
sporadic primary ICH and secondary ICH caused by trauma,
brain tumor, hemorrhagic transformation of ischemic stroke,
vascular malformation, and other factors, even among health
care practitioners. In addition, the relatively young age, low
number of ICH cases, and lack of ICH adjudication in the UKB
make it ill-suited as a validation dataset for this application.
This work marks the continued progression of genetic research
into collagen IV from gene mapping in mendelian disease
through to identification of risk variants for sporadic disease in
the general population. These sequencing results build on ex-
tant GWAS of ICH, demonstrating thatCOL4A1 andCOL4A2
contribute to sporadic ICH not only through as-yet poorly
understood mechanisms related to associations at common
variants but also potentially by rare variants that alter protein
structure. Our observations from both sequenced datasets as
shared through this article add substantially to our un-
derstanding of the burden and spectrum of COL4A1/COL4A2
rare variation in sporadic ICH. Given the significance of 13q34
in both rare and common variant studies of ICH, studies
building on our observationsmay link the pathogenic processes
that underlie monogenic and polygenic ICH risk at this locus.
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